Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice

A recent type 1 diabetes (T1D) clinical trial of rituximab (a B cell-depleting anti-CD20 antibody) achieved some therapeutic benefit in preserving C-peptide for a period of approximately nine months in patients with recently diagnosed diabetes. Our previous data in the NOD mouse demonstrated that co...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarikonda, Ghanashyam, Sachithanantham, Sowbarnika, Manenkova, Yulia, Kupfer, Tinalyn, Posgai, Amanda, Wasserfall, Clive, Bernstein, Philip, Straub, Laura, Pagni, Philippe P., Schneider, Darius, Calvo, Teresa Rodriguez, Coulombe, Marilyne, Herold, Kevan, Gill, Ronald G., Atkinson, Mark, Nepom, Gerald, Ehlers, Mario, Staeva, Teodora, Garren, Hideki, Steinman, Lawrence, Chan, Andrew C., von Herrath, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566105/
https://www.ncbi.nlm.nih.gov/pubmed/23405091
http://dx.doi.org/10.1371/journal.pone.0054712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566105/
https://www.ncbi.nlm.nih.gov/pubmed/23405091
http://dx.doi.org/10.1371/journal.pone.0054712

Ejemplares similares